A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19

Crit Care. 2022 Jul 28;26(1):229. doi: 10.1186/s13054-022-04096-9.

Authors

Gebhard Wagener^#¹, Monica P Goldklang^#¹, Adam Gerber¹, Katerina Elisman¹, Katherine A Eiseman^{1

2}, Laura D Fonseca¹, Jeanine M D'Armiento³

Affiliations

¹ Department of Anesthesiology, Columbia University Irving Medical Center, 622 West 168th Street, PH 5, New York, NY, 10032, USA.
² Columbia University Vagelos College of Physicians and Surgeons, New York-Prebysterian Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.
³ Department of Anesthesiology, Columbia University Irving Medical Center, 622 West 168th Street, PH 5, New York, NY, 10032, USA. [email protected].

^# Contributed equally.

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Angiotensin I
Antifibrinolytic Agents*
Blood Loss, Surgical
COVID-19*
Double-Blind Method
Humans
Peptide Fragments
Pilot Projects
Tranexamic Acid*
Treatment Outcome

Substances

Antifibrinolytic Agents
Peptide Fragments
Tranexamic Acid
Angiotensin I
angiotensin I (1-7)

Associated data

ClinicalTrials.gov/NCT04401423